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ABSTRACT 
Probiotic are defined as live organisms, which confer benefits to the host. Their efficiency was demonstrated for the treatment of gastrointestinal disorders, 
respiratory infections, and allergic symptoms, but their use is mostly limited to bacterial and viral diseases. During the last decade, probiotic as means for the 
control  of  parasite  infections  were  reported  covering  mainly  intestinal  diseases  but  also  some  nongut  infections  that  are  all  of  human  and  veterinary 
importance. In most cases, evidence for a beneficial effect was obtained by studies using animal models. In a few cases, cellular interactions between probiotic 
and pathogens or relevant host cells were also investigated using in vitro culture systems. WHO have given special guidelines for probiotic. Bifidobacteria 
have been studied for their efficacy in the prevention and treatment of a broad spectrum of animal and/or human gastrointestinal disorders, such as colonic 
transit disorders, intestinal infections, and colonic adenomas and cancer. 
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INTRODUCTION          
There  is  evidence  that  the  oral  consumption  of 
microorganisms produces a protective effect on the gut flora.  
Probiotic  are  defined  as  the  viable  microorganisms  that 
exhibit  a  beneficial  effect  on  the  health  of  the  host  by 
improving its intestinal microbial balance. The term probiotic 
is defined by a United Nation and World Health Expert Panel 
as live microorganisms which when administered in adequate 
amounts confer a health benefit on the host. Probiotic are also 
defined as the viable microorganisms that exhibit a beneficial 
effect  on the health of the host by improving its intestinal 
microbial balance. The concept of probiotics. probably dates 
back  to  1908,  when  Noble  Prize  winner  Eli  Metchnikoff 
suggested  that  the  long  life  of  Bulgarian  peasants resulted 
from their consumption of fermented milk products.
 The term 
probiotic was first used in 1965, by Lilly and Stillwell for 
describing  substances  secreted  by  one  organism  which 
stimulate  the  growth  of  another.
    Marteau  et  al,  in  2002 
defined  them  as  microbial  preparations  or  components  of 
microbial  cells  that  have  a  beneficial  effect  on  health  and 
well  being.
  Humans  live  in  close  association  with  vast 
numbers of micro-organisms. The GIT harbors a rich flora of 
more  than  500  different  bacterial  species,  stimulating  the 
immune  system,  the use  of  antibiotics, immunosuppressive 
therapy and irradiation, amongst other means of treatment, 
may cause alterations in the composition and have effect on 
the flora. Therefore, the introduction of beneficial bacterial 
species into the GI tract may be a very attractive option to re-
establish the microbial equilibrium and prevent disease
1,2. 
Properties 
an  ideal  probiotic  preparation  should  have  the  following 
properties.
 For adequate amount of health benefits, a dose of 
five billion colony forming units a day (5x10
 9 CFU/day has 
been  recommended,  for  at  least  five  days.  The 
microorganisms  used  in  probiotic  preparations  should  be 
generally recognized as safe (GRAS), they should be resistant 
to  bile,  hydrochloric  acid  and  pancreatic  juice,  have  anti-
carcinogenic  activity  and  stimulate  immune-system,  have 
reduced intestinal permeability, produce lactic acid, able to 
survive  both acidic conditions of the stomach and alkaline 
conditions of the duodenum. Foods for human consumption 
that  contain  mainly  lactic  acid  bacteria  include  fermented 
milks, cheeses, fruit juices, wine, and sausages. Single and 
mixed cultures of live microorganisms are used in probiotics 
preparations.
 Experiments into the potential health effects of 
supplemental  probiotics  include  the  molecular  biology  and 
genomics of Lactobacillus in immune function, cancer, and 
antibiotic-associated  diarrhoea,  travellers'  diarrhoea, 
paediatric  diarrhoea,  Inflammatory  bowel  syndrome  and 
bowel syndrome.  For testing of a probiotic using specific 
strain under study
3. 
Stain  Identification:  Guidelines  For  The  Evaluation  Of 
Probiotics 
In order to claim that a food has a probiotic  effects, Joint 
FAO/WHO  (Food  and  Agriculture  Organization  of  the 
United Nations/ World Health Organization) Working Group 
generate guidelines for their evaluation. A scheme outlining 
these guidelines for the evaluation of probiotics for food use 
is shown in figure 1.  
DNA-DNA hybridization is the reference method to specify 
that  a  strain  belongs  to  a  species:  however,  as  it  is  time 
consuming and beyond the resources of many laboratories, 
requiring a large collection of reference strains, the use of 
DNA sequence encoding 16S rRNA is suggested as a suitable 
substitute.  Strain  typing  has  to  be  performed  with  a 
reproducible  genetic  method  or  using  a  unique  phenotypic 
trait.  Pulsed  Field  Gel  Electrophoresis  (PFGE)  is  the  gold 
standard. Randomly Amplified Polymorphic DNA (RAPD) 
can also be used.  
In- Vitro Tests To Screen Potential Probiotics  
In-vitro tests are useful to gain knowledge of strains and the 
mechanism of the probiotic effect. It was noted that in- vitro 
data  available  for  particular  strains  are  not  sufficient  for 
describing them as probiotic. Probiotics for human use will 
require  substantiation  of  efficacy  with  human  trials. 
Appropriate target- specific in- vitro tests that correlate with 
in- vivo results are recommended. Conway et al. correlated 
the in- vitro bile salts resistance with the gastric survival in- Arora Neha et al. IRJP 2012, 3 (1) 
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vivo. A list of the main currently used in- vitro tests for the 
study of probiotic strains is as follows- Resistance to gastric 
acidity,  Bile  acid  resistance,  Adherence  to  mucus  and/  or 
human epithelial cells and cell lines, Antimicrobial activity 
against  potentially  pathogenic  bacteria,  Ability  to  reduce 
pathogen adhesion to surfaces, Bile  salt hydrolase activity, 
Resistance  to  spermicides  (applicable  to  probiotics  for 
vaginal use).   
Safety Consideration 
Probiotics are viable organisms, and therefore it is feasible 
that they could infect the host. Historical data indicates that 
probiotic lactobacilli and bifidobacteria associated with food 
have been considered to be safe
4. Their occurrence as normal 
commensals  of  the  mammalian  micro  biota  and  their 
established safe use in diverse food and supplement products 
worldwide support this conclusion. However, probiotics may 
theoretically  be  responsible  for  four  types  of  side  effects. 
Systemic  infection,  deleterious  metabolic  activities, 
Excessive  immune  stimulation  in  susceptible  individuals, 
Gene transfer.  
Phase 2 Clinical Studies 
Standard methods for clinical evaluations are comprised of 
Phase1 (safety), Phase2 (efficacy), Phase3 (effectiveness) and 
Phase4 (surveillance). Phase2 studies, generally in the form 
of  randomized,  double  blind,  placebo-controlled  (DBPC) 
design,  measure  efficacy  compared  with  placebo.  The 
outcomes  for  the  individual  should  be  a  statistically  and 
biologically significant improvement in condition, symptoms, 
signs, well beings, or quality of life, reduced risk of disease 
or  longer  time  period  to  the  next  occurrence,  or  faster 
recovery from illness. More clinical evidence of this type is 
needed  to  gain  credibility  among  the  broader  medical 
community. These need to provide a physician with the name 
of the strain, its product formulation, and the specific use for 
which it has been shown to be effective. 
Phase 3 Clinical Studies 
In other words, Phase3 studies require careful planning and 
an evaluation of multiple endpoints before probiotics should 
be  discarded  from  the  health  care  armamentarium.  The 
performance of more Phase3 studies on probiotic strains is 
required to determine fully their place, if any, in the treatment 
and  prevention  of  more  serious  clinical  conditions  and 
whether or not this approach can replace or complement
5. 
Health Claims And Labelling 
Currently, in most countries, only general health claims are 
allowed on foods containing probiotics, specific health claims 
are  allowed  on  drug-approved  probiotics  that  have  gone 
through Phase3 clinical studies. Such specific health claims 
should be permitted on the label and promotional materials. 
For example, a specific claim that states a probiotic reduce 
the  incidence  and  severity  of  rotavirus  diarrhea  in  infants 
would be more informative to the consumer than a general 
claim that states improve gut health. 
Corporate  contact  details  for  consumer  information 
ISAPP’S role for establishment of standards for probiotic 
products  
There  are  a  number  of  problems  related  to  the  quality  of 
commercial  products  of  probiotics.  These  products  do  not 
adequately  meet  label  requirements  Problems  exists  in  the 
following areas- 1.The number of live microbes of each strain 
delivered through the end of shelf life is often not accurately 
reflected on the label. 2. Microbes contained in the product 
are not always named in accordance with scientifically valid 
nomenclature.  3.  Claims  of  efficacy  are  not  always 
adequately substantiated. 4. Use of the term ‘probiotic’on the 
labels  of  products  with  no  established  record  of  a 
physiological  (health)  benefit  in  humans.  Although  a 
scientifically  recognized  consensus  definition  of  the  term 
‘probiotic’ was established by an FAO Expert Consultation, 
the  term  is  misused  on  products  that  lack  a  minimum  of 
studies  validating  efficacy.  Acceptance  and  enforcement 
world wide of a ‘Standard of Identity’  for use of the term 
‘probiotic’ would go a long way toward bolstering consumer 
confidence  when  purchasing  probiotic  products,  building  a 
strong foundation for a growing industry and informing the 
legislation for claims.  
Standards of identity for the term probiotic 
Safe, Microbiologically defined, Impact on human health or 
physiology documented by at least one controlled study in 
humans of suitable size and statistical power to be considered 
valid  by  experts  in  the  field.  Product  labels  accurately 
indicate the genus, species and strain of all contained types of 
microbes  according  to  nomenclature  accepted  by  the 
microbiological  community.  Product  labels  accurately 
indicate  per  serving  or  per  dose  levels  of  each  probiotic 
microbe  contained in the  product  through  the  end  of  shelf 
life. Any efficacy statements made on product labels or in 
promotional  materials  or  websites  are  truthful  and  not 
misleading and are based on scientifically valid studies.  
Probiotic Selection 
Probiotic strain selection shown in Figure 2
Comparison Between Probiotic, Probiotic And Symbiotic
6,7 
Term  Definition   Examples  Advantages  Possible Future  developments 
Probiotic  A live microbial food supplement 
which beneficially affect host 
animal by improving its intestinal 
microbial balance 
Lactobacilli, 
Bifidobacteria 
Enterococci 
streptococci 
Strain  may  have  proven 
health  values  .Useful 
when  gut  flora  may  be 
compromised 
New  product  developments  based  on 
synbiotics, that may improve probiotic survival 
Prebiotic  A non –digestible food ingredient 
that  beneficially  affects  the  host 
by  selectively  stimulating  the 
growth  or  activity  of  one  or  a 
limited  number of  bacteria in the 
colon  ,and  thus  improves  host 
health  
Fructo-
oligosaccarides 
(FOS),inulin,galacto
-oligosaccarides 
 
 
Genus  –level  changes 
occur  in  gut  flora 
.product  survival  not 
problematic.low  dose 
required  and  can  be 
incorporated  into  many 
different  food  delivery 
system 
Manufactur  of  novel  multiple-function 
prebiotics,  that  may  stimulate  the  “beneficial 
flora;  exert  antiadhesiv  properties  attenuate 
pathogen  virulence.probiotic  derived  from 
dietary fiber –type polysaccarides 
Synbiotic  A  mixture  of  pro-and  prebiotics 
which beneficially affects the host 
by  improving  the  survival  and 
implantation  of  live  microbial 
dietary  supplements  in  the 
gastrointestinal tract. 
Fructooligosacchari
des+(FOS),+bifidob
acteria;Lactilol+lact
obacilli 
Dual  effect  of  both 
entities  .Probiotic 
survival  should  be 
improved 
Design  of  new  symbiotic  through  molecular 
engineering  (based  on  specific  probiotic 
enzyme) 
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Factor Affecting Probiotic 
Physiological state 
The  physiological  state  of  bacteria  when  prepared  and 
remaining in a product itself are important factors for survival 
of the probiotic. Dryness in a food product keeps the bacteria 
in  a  relatively  quiescent  state  during  storage,  while  a  wet 
product  establishes  potentially  active  metabolism. 
Temperature  affects  shelf  life  of  the  bacteria,  with  low 
temperature  providing  conditions  for  possible  long  term 
survival. 
Temperature 
 During  processing,  temperatures  over  45–50°C  will  be 
detrimental to probiotic survival, this means that the higher 
the  temperature,  the  shorter  the  time  period  of  exposure 
required to severely decrease the numbers of viable bacteria, 
ranging  from  hours  or  minutes  at  45–55°C  to  seconds  at 
higher temperatures. Therefore it is obvious that probiotics 
should  be  added  downstream  of 
heating/cooking/pasteurization processes in food manufacture 
to avoid the high temperatures. 
pH 
Some  bacteria  like  Lactobacilli  and  bifidobacteria  can 
tolerate lower pH levels  because produce organic acid and 
products from carbohydrate metabolism. Indeed, numerous in 
vitro and in vivo studies have demonstrated that in gastric 
transit where the cells are exposed to low pH values and with 
a time of exposure relatively short, some probiotic organisms 
can survive. In fermented milks and yogurts with pH values 
between  3.7  and  4.3.  lactobacilli  are  able  to  grow  and 
survive,  while  Bifidobacteria  tend  to  be  less  acid  tolerant, 
with most species surviving poorly in fermented products at 
pH levels below 4.6. 
Water activity 
The  higher  moisture  levels  and  water  activity,  the  lower 
survival  of  probiotics.  There  is  a  substantial  interaction 
between water activity and temperature with respect to their 
impact on the survival of quiescent probiotics. As the storage 
temperature is increased, the detrimental impact of moisture 
is magnified.  
Oxygen 
Maintaining  probiotic  viability  in  moderate  water  activity 
foods  (0.4–0.7)  is  a  great  challenge  and  solutions  such  as 
microencapsulation  or  incorporation  of  probiotics  into  fat 
phases  of  products  can  provide  improved  survival.      Most 
probiotic bifidobacteria do not grow well in the presence of 
oxygen,  although,  many  bifidobacteria  have  enzymatic 
mechanisms  to  limit  the  oxygen  toxicity.  For  oxygen 
sensitive  strains,  some  strategies  can  be  used  to  prevent 
oxygen  toxicity  in  food  products.  Antioxidant  ingredients 
have been shown to improve probiotic survival, as well as the 
use  of  oxygen  barrier  or  modified-atmosphere  packaging. 
Therefor, it is advisable to minimize processes that are highly 
aerating, particularly when using bifidobacteria. Toxicity of 
ingredients.  Interactions  between  probiotics  and  other 
ingredients  could  happen  and  those  interactions  can  be 
protective,  neutral,  or  detrimental  to  probiotic  stability. 
Obviously,  the  inclusion  of  antimicrobial  preservatives  can 
inhibit probiotic survival and elevated levels of ingredients 
such as salt, organic acids, and nitrates can inhibit probiotics 
during storage, while starter cultures can sometimes inhibit 
the  growth  of  probiotics  during  fermentation  through  the 
production of specific bacteriocins. 
Growth factors, protective, and synergistic ingredients 
Probiotic  lactobacilli  and,  in  particular,  bifidobacteria  are 
only weakly proteolytic and grow relatively slowly or poorly 
in milk. The growth of bifidobacteria can be improved by the 
presence  of  suitable  companion  cultures,  which  can aid in 
protein  hydrolysis  and  through  the  production  of  growth 
factors.  Some  growth  substrates  such  as  carbon  sources, 
nitrogen sources, and growth factors or antioxidants, minerals 
and vitamins can be added to improve growth. Finally, the 
food matrix itself can be protective like in the cheese, where 
the  anaerobic  environment,  high  fat  content  and  buffering 
capacity of the matrix helps to protect the probiotic cells both 
in the product and during intestinal transit. 
Freeze–thawing 
The damages made to cell membranes freezing probiotics is 
detrimental  to  survival,  and  also  can  make  the  cells  more 
vulnerable to environmental stresses. To prevent or at least 
mitigate cell injury, protectants are usually added to cultures 
to  be  frozen  or  dried.  Once  frozen,  probiotics  can  survive 
well over long shelf lives in products such as frozen yogurts 
and ice-cream. Using alternative methods of freezing, such as 
slow-cooling  rates  or  pre-freezing  stress,  can  significantly 
improve  cell  survival.  Repeated  freeze–thawing  cycles  are 
highly detrimental to cell survival and should be avoided. 
Shear forces 
Probiotic  lactobacilli  and  bifidobacteria  are  Gram-positive 
bacteria with thick cell walls that are able to tolerate the shear 
forces generated in most standard food production processes 
such  as  high-speed  blending  or  homogenization  that  may 
result in cell disruption and losses in viability.
  
Mechanism Of Action Of Probiotic  
Several mechanisms have been postulated regarding action of 
Probiotics.  Partial  lactose  digestion  and  stimulation  of  the 
intestinal mucosal lactase activity has been postulated as a 
possible  mechanism  against  some  types  of  diarrhoea. 
Lactobacilli used in the fermented milk industry have active 
beta-galactosidase  to  decrease  the  lactose  concentration  in 
dairy  products,  which  may  affect  the  severity  of  osmotic 
diarrhea due to organisms as rotavirus.
 Lactic acid bacteria 
produce  several metabolites  like  fatty  free  acids,  hydrogen 
peroxide, bacteriocins etc. which prevent the growth of food 
borne  pathogens  in  dairy  products  Probiotics  can  also  use 
enzymatic mechanisms to modify toxin receptors and block 
toxin  mediated  pathology.
  Probiotic  agents  also  prevent 
colonization of pathogens The other suggested mechanisms 
for  the  effect  on  intestinal  microflora  are  lowering  the 
intestinal pH,release of gut protective metabolites, regulation 
of intestinal motility and mucus production. Gastrointestinal 
mucosa  is  the  primary  interface  between  the  external 
environment  and  the  immune  system.  Whenever  intestinal 
microflora reduces, antigen transport is increased indicating 
that the normal gut micro flora maintains gut defences. The 
non-pathogenic  probiotic  bacteria  interact  with  the  gut 
epithelial  cells  and  the  immune  cells  to  start  the  immune 
signals.  These  bacteria  must  interact  with  M  cells  in  the 
Peyers patches, with gut epithelial cells, and with associated 
immune  cells.  Probiotic  bacteria  have  been  shown  to 
modulate  immunoglobulin  production.  Secretory  IgA  plays 
an important role in mucosal immunity, contributing to the 
barrier against pathogenic bacteria and viruses. The increase 
in  the  number  of  IgA  producing  cells  was  the  most 
remarkable property induced by probiotic organisms and also Arora Neha et al. IRJP 2012, 3 (1) 
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by fermented milk yogurt. T independent IgA induction has 
also been demonstrated
8. The increase in profiles of certain 
cytokines (TNF- α IFN- γ, IL-10) has also been observed due 
to  stimulation  with  probiotic  bacteria
9.  The  release  of 
cytokines  is  induced  to  up  or  down  regulate  the  immune 
responses  and  maintain  intestinal  homeostasis.  Interactions 
between  probiotic  micro-organisms  and  GALT(Gut 
associated  lymphoid  tissue),  mechanisms  of 
immunomodulation and anti-inflammatory properties are not 
yet fully understood.
   
Potential Effect Of Probiotic 
Diarrhoea 
Some probiotic have been shown in preliminary research to 
possibly  treat  various  forms  of  gastroenteritis.  They  might 
reduce  both  the  duration  of  illness  and  the  frequency  of 
stools. Fermented milk products also reduce the duration of 
symptoms
10. 
Antibiotic-associated diarrhoea 
Antibiotic  associated  diarrhoea  (AAD)  results  from  an 
imbalance  in  the  colonic  microbiota  caused  by  antibiotic 
therapy.  Microbiota  alteration  changes  carbohydrate 
metabolism with decreased short term fatty acid absorption 
and an osmotic diarrhoea as a result. Another consequence of 
antibiotic  therapy  leading  to  diarrhoea  is  overgrowth  of 
potentially  pathogenic  organisms  such  as  Clostridium 
difficult. Probiotic treatment might reduce the incidence and 
severity  of AAD as indicated in several metanalysis
11. For 
example,  treatment  with  probiotic  formulations  including 
Lactobacillus rhamnosus may reduce the risk of antibiotic-
associated  diarrhoea,  improve  stool  consistency  during 
antibiotic  therapy,  and  enhance  the  immune  response  after 
vaccination.  However,  further  documentation  of  these 
findings  through  randomized  double-blind,  placebo-
controlled trials are required to confirm specific effects and 
attain  regulatory  approval,  which  currently  does  not  exist. 
Potential efficacy of probiotic AAD prevention is dependent 
on the probiotic strain(s) used and on the dosage
12  Up to a 
50%  reduction  of  AAD  occurrence  has  been  found  in 
preliminary studies. No side-effect have been reported in any 
of these studies. Caution should, however, be exercised when 
administering probiotic supplements to immunocompromised 
individuals  or  patients  who  have  a  compromised  intestinal 
barrier. 
Lactose intolerance 
As  lactic  acid  bacteria  actively  convert  lactose  into  lactic 
acid,  ingestion  of  certain  active  strains  may  help  lactose 
intolerant individuals tolerate more lactose than they would 
have otherwise
13. 
Colon cancer 
In  laboratory  investigations,  some  strains  of  LAB 
Lactobacillus delbruekiti suspension have demonstrated anti-
mutagenic effects thought to be due to their ability to bind 
with hetrocyclic  amines  which are  carcinogenic  substances 
formed  in  cooked  meat  Animal  studies  have  demonstrated 
that some LAB have evidence for acting against colon cancer 
in rodents, though human data are inconclusive. Some human 
trials  hypothesize  that  the  strains  tested  may  exert  anti-
carcinogen effects  by decreasing the activity of an enzyme 
called glucuronidase.  
Cholesterol 
Animal studies have demonstrated the efficacy some strains 
of  LAB  to  be  able  to  lower  serum  cholesterol  levels, 
presumably by breaking down bile in the gut thus inhibiting 
its reabsorption  (which  enters  the  blood  as  cholesterol).  A 
meta-analysis that included five double blind trials examining 
the short term (2-8weeks) effects of a yogurt with probiotic 
strains on serum cholesterol levels found a minor change of 
8.5 mg/dL (0.22 mmol/L) (~4% decrease) in total cholesterol 
concentration,  and  a  decrease  of  7.7 mg/dL  (0.2 mmol/L) 
(~5%  decrease)  in  serum  LDL  concentration.    A  slightly 
longer study evaluating the effect of a yogurt with probiotic 
strains  on  twenty-nine  subjects  over  six  months  found  no 
statistically significant differences in total serum cholesterol 
or  LDL  values.  However,  the  study  did  note  a  significant 
increase  in  serum  HDL  from,  50 mg/dL  (1.28 mmol/L)  to 
62 mg/dL  (1.6 mmol/L)  following  treatment.  This 
corresponds to a possible improvement of LDL/HDL ratio
14. 
Studies  specifically  on  hyper-lipidemic  subjects  are  still 
needed. 
Blood pressure 
Although not a confirmed effect, some studies have indicated 
that consumption of milk fermented with various strains of 
LAB may result in modest reductions in blood pressure, an 
effect  possibly  related  to  the  ACE-inhibitor  like  peptidase 
produced during fermentation.  
Immune function and infections 
Some  strains  of  LAB  may  affect  pathogen  by  means  of 
competitive  inhibition  (i.e.,  by  competing  for  growth)  and 
there is evidence to suggest that they may improve immune 
function by increasing the number of IgA-producing plasma 
cells,  increasing  or  improving  phagocytosis  as  well  as 
increasing  the  proportion  of  T-lymphocytes  and  Natural 
Killer cells
15.  
Helicobacter pylori 
Some strains of LAB may affect infections (which may cause 
peptic  ulcer)  in  adults  when  used  in  combination  with 
standard medical treatments, but there is no standard in medic 
al practice or regulatory approval for such treatment
16 . 
Inflammation 
Some  strains  of  LAB  may  modulate  imflammation  and 
hypersensitivity  responses,  an  observation thought to  be  at 
least  in  part  due  to  the  regulation  of  cytokines  function. 
Clinical studies suggest that they can prevent reoccurrences 
of inflammation bowel disease in adults, as well as improve 
milk allergies. They are not effective for treating eczema, a 
persistent skin inflammation. How probiotics may influence 
the  immune  system  remains  unclear,  but  a  potential 
mechanism  under  research  concerns  the  response  of  T  –
lymphocytes to pro-inflammatory stimuli.  
Bacterial growth under stress 
In a study done to see the effects of stress on intestinal flora, 
rats that were fed probiotics had little occurrence of harmful 
bacteria  latched  onto  their  intestines  compared  to  rats  that 
were fed sterile water.  
Irritable bowel syndrome and colitis 
In one study, a commercial strain of Bifidobacterium infantis 
improved  some  symptoms  of  irritable  bowel  syndrome  in 
women.  A  separate  small  study  showed  that  a  strain  of 
lactobacillus plantarum may also be effective in reducing IBS 
symptoms. A study  focused  on    Bifidobacterium animalis 
showed a reduction in discomfort and bloating in individuals 
with  constipation-predominant  IBS,  as  well  as  helping  to 
normalize  stool  frequency  in  said  individuals.  For 
maintenance  of  remission  of  ulcerative  colitis,  Mutaflor Arora Neha et al. IRJP 2012, 3 (1) 
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(E.coli  Nissle  1917)  randomized  clinical  studies  showed 
equivalence of Mutaflor and mesalazine (5-ASAs).
 
Application of probiotic
16 
Examples of various stains that have been positively affect 
health. 
 
Indication  Genus , species, strain 
Inflammatory bowel 
condition 
Eight strain combination of 
3bifidobacterium strains,4 
lactobacillus strains and 
s.thermophilus 
Antibiotic associated 
diarrhea 
S cerevisiae,L rhamnosus, L casei, 
L acidophilus 
Gut transit time  Bifidus regularise 
General wellness  L reuteri,L casei 
Lactose intolerance  L bulgarius,S thermophilus 
Immune support  B lactis, L casei 
Irritable  bowel syndrome 
symptoms 
B infantis 
L= Lactobacillus strain, B = bifidobacteium strain, 
S=Streptococcus thermophilus strain 
 
CONCLUSION  
The concept that probiotics could control the development of 
eukaryotic  pathogens  is  Emerging.  Therapeutic  approaches 
with probiotic  could help to reduce the risks of infestation by 
specific  parasites  or  complement  classical  anti-parasite 
treatments. Probiotic therapy has already made its way in the 
treatment of number of conditions-Infectious, inflammatory, 
neoplastic and allergic. There is a long list of potentials of 
giving probiotics in a number of these conditions. But before 
bringing  probiotic  into  routine  usage,  proper  evaluation  of 
these  products  is  essential.  Several  important  criteria  and 
standards  regarding  quality  and reliability  have  to  be  met. 
Thus  future  well  designed  placebo  controlled  studies  with 
validated results are required for ascertaining the true health 
benefits  of  these  products.  The  important  point  is  careful 
selection of the probiotic agent, its dose standardization and a 
thorough knowledge of its beneficial effects over and above 
the toxic effects, so that this traditional therapy proves to be 
an  effective  tool  for  medical  therapy. 
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